Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $102 million versus the consensus estimate of $100.29 million.

GUIDANCE:

Halozyme Therapeutics sees FY2022 EPS of $2.05-$2.20, versus the consensus of $2.18. Halozyme Therapeutics sees FY2022 revenue of $530-560 million, versus the consensus of $554.2 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.